Free Trial
NASDAQ:ABVC

ABVC BioPharma Q2 2025 Earnings Results & Report

ABVC BioPharma logo
$0.94 +0.03 (+3.30%)
As of 03:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ABVC BioPharma reported Q2 2025 earnings on August 13, 2025. The company reported EPS of -$0.13.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

ABVC BioPharma EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ABVC BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ABVC BioPharma Q2 2025 Earnings FAQ

ABVC BioPharma (NASDAQ:ABVC) reported earnings of -$0.13 per share for Q2 2025. The report was announced on Wednesday, August 13, 2025.

ABVC BioPharma Earnings Headlines

/C O R R E C T I O N - WallachBeth Capital LLC/
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
ABVC BioPharma Delays Quarterly SEC Filing
See More ABVC BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ABVC BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ABVC BioPharma and other key companies, straight to your email.

About ABVC BioPharma

ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biopharmaceutical company focused on developing botanical drug candidates and medical devices. The company conducts research and development through its subsidiaries and external partners.

Its pipeline includes ABV-1504, a botanical drug candidate being developed for major depressive disorder, and ABV-1505, a candidate for attention-deficit/hyperactivity disorder. These products remain in development and are not described as approved treatments.

Founded in 2015 and headquartered in Fremont, California, ABVC also pursues development opportunities in oncology and other therapeutic areas. Its work includes collaborations and licensing arrangements to advance its product candidates.

View ABVC BioPharma Profile